BOSTON, March 9, 2017 /PRNewswire-USNewswire/ -- In a recent ARC patient study, 79% of patients said with better information and access they would consider participating in a clinical trial. The major ...

Lorena Saelices Gómez is a Principal Investigator at UT Southwestern (TX, USA), whose research group focuses on transthyretin amyloidosis (ATTR amyloidosis) and other amyloid diseases. After earning a ...

Isabelle Lousada was in her early 30s when she collapsed at her Philadelphia wedding in 1995. A London architect, she had suffered a decade of mysterious symptoms: tingling fingers, swollen ankles, ...

Transthyretin amyloidosis (ATTR) is a rare, progressive and highly aggressive degenerative disease. It is caused by the misfolding of a specific protein, leading to its toxic accumulation in the form ...

Amyloid heart disease occurs when amyloid fibrils build up in the heart, making it more difficult for the heart to pump blood around the body. Eventually, this can lead to heart failure. People can ...

Novel directed therapies for transthyretin cardiac amyloidosis (ATTR) have been shown to improve outcomes and reduce the long-term negative effects of unchecked amyloid proliferation in patients with ...

The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy transthyretin moves hormones through blood and spinal fluid, misfolded ...

Light chain amyloidosis is not cancer, but cancer drugs are this rare disease’s standard of care. The patient need for new treatment options has sparked R&D efforts at biotech and big pharmaceutical ...

The newest treatment approved to fight Alzheimer’s disease is a kind of drug called an anti-amyloid. It works directly on what may cause the disease, instead of just the symptoms. Anti-amyloids are ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. The Big ...